CN101302204A - Quinazolone compound, composition and application including the same - Google Patents

Abstract

Quinazolinones of formulae (1c and 1d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.

Description

Quianzolinones, comprise this compound compositions and application

Patent application of the present invention is dividing an application of the 00817783.X Chinese patent application submitted on October 26th, 2000.

Technical field

The present invention relates to the Quinazol derivative as the inhibitor of mitotic kinesins KSP, it can be used for treating cell proliferation disorders, as cancer, hyperplasia, restenosis, megalocardia, Immunological diseases and inflammation.

Background of invention

Along with the 1950's in early days by a kind of with antimalarial character isolated quinolizidine alkaloid--3-[beta-keto-γ-(3-hydroxyl-2-piperidyl)-propyl group in the plant of Asia well known]-the illustrating of 4-Quinazolone structure, stimulated the development of the medical chemistry of quinazoline derivant.In seeking the process of other antimalarial drugs, the various quinazoline compounds that are substituted have been synthesized.Wherein particularly importantly synthesized 2-methyl-3-o-tolyl-4-(3H)-Quinazol derivative.This compound is also referred to as methaqualone, though invalid to protozoon, find it is a kind of potent soporific.

Because the introducing of methaqualone with and as the discovery of soporific, the begun one's study pharmacologically active of quinazolinone and related compound thereof of people.Existing known quinazolinone and derivative thereof have different widely physiological properties, comprising sleep peacefully, calmness, analgesia, spasmolytic, antibechic and anti-inflammatory activity.

The Quinazol derivative that has been described concrete biologic applications comprises the 5th, 147, No. 875 United States Patent (USP)s, and it discloses 2-(the substituted-phenyl)-4-oxo quinazoline with bronchiectasis activity.The 3rd, 723,432,3,740,442 and 3,925, No. 548 United States Patent (USP)s have been described 1-replacement-4-aryl-2 (1H)-Quinazol derivative that a class can be used as anti-inflammatory drug.European patent publication EP 0 056 637 B1 disclose a class and have been used for the treatment of hypertensive 4 (3H)-Quinazol derivatives.European patent publication EP 0 884 319A1 have described the pharmaceutical composition of quinazoline-4-one derivatives, and it can be used for treating central nervous system that neurodegenerative disease, psychotic disorder and medicine and alcohol the brings out peripheral nervous disease of unifying.

The quinazolinones medicine is to be used for the treatment of a kind of in numerous medicines of cell proliferation disorders (comprising cancer).For example, PCT WO96/06616 discloses the pharmaceutical composition that comprises Quinazol derivative, and it is used to suppress vascular smooth muscle cell proliferation.PCT WO 96/19224 has used this identical Quinazol derivative to suppress mesengial cell proliferation.The 4th, 981,856,5,081,124 and 5,280, No. 027 United States Patent (USP) has been described the application of Quinazol derivative inhibition thymidylate synthetase, and methylating of described enzyme catalysis deoxyuridine list phosphoric acid produces the synthetic necessary thymidine list phosphoric acid of DNA.The 5th, 747,498 and 5,773, it is the Quinazol derivative of the cancer of feature that No. 476 United States Patent (USP)s have been described the overactivity or the inappropriate activity that are used for the treatment of with the tyrosine receptor kinase.The quinazoline compound that the 5th, 037, No. 829 U.S. Patent Publications (1H-pyrroles-1-ylmethyl) replace, it is used for the treatment of the cancer that takes place in epithelial cell.PCT WO98/34613 has described the composition that comprises Quinazol derivative, and it is used to weaken neovascularization and treatment malignant tumour.The 5th, 187, No. 167 U.S. Patent Publications comprise the pharmaceutical composition of quinazoline-4-one derivatives, it has anti-tumor activity.

Other are used for the treatment of the treatment for cancer agent and comprise Taxan and vinca alkaloids.Taxan and vinca alkaloids act on the microtubule, and this microtubule is present in the various cellularstructures.Microtubule is the primary structure composition of mitotic spindle.Mitotic spindle is responsible for the genomic distribution of template in one of two daughter cells that cell fission produced of duplicating.Suppose that these medicines cause the cancer cells splitted is suppressed to the destruction of mitotic spindle, and bring out cancer cell death.Yet microtubule forms the cellularstructure of other types, comprises the track of carrying in the cell that is used for nerve process.Because these medicines are target mitotic spindle specifically not,, limited their application so also produce some side effects.

The specificity that improves cancer treatment drugs is quite interesting, and this is because if can reduce and the relevant side effect of these medicines of administration, can realize higher treatment benefit.Traditionally, the huge raising in the cancer therapy is relevant with the therapeutical agent that identifies by new mechanism effect.This example wherein not only comprises Taxan, but also comprises the camptothecine as the topoisomerase I inhibitor.By this two classes medicine, mitotic kinesins is very attractive for new cancer therapy drug.

Mitotic kinesins is that mitotic spindle forms and the necessary enzyme of function, but is not the part of other micro-tubular structures usually, for example in nerve process.Mitotic kinesins all plays basic effect in mitotic all stages.These enzymes are Conversion of energy that the ATP hydrolysis is discharged for driving " molecular moter " of the mechanical force that moves along the microtubule direction in the cell goods yard.The catalytic domain that is enough to finish this task is about 340 amino acid whose imporositys.During mitotic division, kinesin is assembled into microtubule the dipolar configuration of mitotic spindle.Kinesin mediation karyomit(e) moves along spindle microtubule, and the structural changes relevant with the mitotic division particular stage in the mitotic spindle.The experiment interference of mitotic kinesins function causes the deformity or the dysfunction of mitotic spindle, and cell is stopped and necrocytosis.

KSP is a kind of in the mitotic kinesins that has identified.It is former that KSP belongs to the microtubule based motor of positive extreme direction (plus end-directed) of evolution conservative type kinesin subtribe, and it is assembled into the bipolar homotype tetramer of being made up of the antiparallel homodimer.During mitotic division, KSP combines with the microtubule of mitotic spindle.Micro-injection can prevent during the fissional prometaphase that at the antibody of KSP spindle pole from separately, producing monopolar spindle, and causing mitotic division to stop, and bringing out the program necrocytosis in people's cell.KSP and relevant kinesin make antiparallel microtubule bunchy in other inhuman biologies, and they are slided each other, force two spindle poles separately thus.The focusing of the elongation of B spindle body and spindle pole place microtubule anaphase that KSP also can mediating.

Existing people has described people KSP (being also referred to as HsEg5) [people such as Blangy, Cell, 83:1159-69 (1995); People such as Whitehead, Arthritis Rheum., 39:1635-42 (1996); People such as Galgio, J.Cell Biol., 135:339-414 (1996); People such as Blangy, J.Biol.Chem., 272:19418-24 (1997); People such as Blangy, Cell Motil Cytoskeleton, 40:174-82 (1998); Whitehead and Rattner, J.Cell Sci., 111:2551-61 (1998); People such as Kaiser, JBC 274:18925-31 (1999); GenBank accession numbers:X85137, NM004523 and U37426], and the fragment of KSP gene (TRIP5) [people such as Lee, Mol Endocrinol., 9:243-54 (1995); GenBank accession number L40372].Existing people has described xenopus KSP homologue (Eg5) and Drosophila KLP61 F/KRP1 30.

Mitotic kinesins is to find and develop the useful target of novel mitotic division chemotherapeutic.Therefore, the purpose of this invention is to provide the method and composition that is used to suppress mitotic kinesins KSP.

Summary of the invention

According to aforesaid purpose, the invention provides the composition and the method that can be used for treating cell proliferation disorders.Said composition is KSP inhibitor, particularly people KSP inhibitor.

In one aspect, the present invention relates to be used for the treatment of cell proliferation disorders, treatment and active relevant disease of KSP kinesin and the method that suppresses the KSP kinesin.This method is used the compound that is selected from following group:

Wherein:

R ₁Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₂And R ₂' be independently selected from hydrogen, alkyl, oxa alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl; Perhaps R ₂And R ₂' form 3-7 unit together to encircle;

R ₃Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl, oxa alkyl, oxa alkyl aryl, replace oxa alkyl aryl, R ₁₅O-and R ₁₅-NH-;

R ₃' be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl and R ₁₅-NH-;

R ₃" be selected from alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₄Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl and R ₁₆-alkylidene group;

R ₅, R ₆, R ₇And R ₈Be independently selected from hydrogen, alkyl, alkoxyl group, halogen, fluoro-alkyl, nitro, dialkyl amido, alkyl sulphonyl, alkylsulfamoyl group, sulfamoyl alkyl, sulfamyl aryl, alkylthio, carboxyalkyl, carboxamide groups, aminocarboxyl, aryl and heteroaryl;

R ₁₅Be selected from alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₁₆Be selected from alkoxyl group, amino, alkylamino, dialkyl amido, N-heterocyclic radical and replace the N-heterocyclic radical.

The disease of available compounds for treating of the present invention comprises cancer, hyperplasia, restenosis, megalocardia, Immunological diseases and inflammation.

In one aspect of the method, the present invention relates to be used to suppress the compound of KSP kinesin.This compound has structure as implied above.

In addition, the present invention also is provided for screening the method in conjunction with the compound of KSP kinesin, for example replaces the combination of The compounds of this invention or the compound that is at war with combining of compound of the present invention.This method comprises mixes compound of the present invention, KSP kinesin and at least a drug candidate, measures the combination of candidate's biologically active drug to the KSP kinesin then.

In a further aspect, the invention provides the method that is used to screen KSP kinesin active regulator.This method comprises mixes compound of the present invention, KSP kinesin and at least a drug candidate, measures candidate's biologically active drug then to the active effect of KSP kinesin.

Description of drawings

Fig. 1 has described the total synthetic method of The compounds of this invention.

Fig. 2 has described the synthetic route of quinazolinone KSP inhibitor.

Fig. 3 has described the representative chemical structure of quinazolinone KSP inhibitor.

Fig. 4 has described the asymmetric synthesis route of pure basically single enantiomer.

Fig. 5 has described the synthetic route of sulphonamide (5a), carbamate (5b), urea (5c) and primary and secondary amine R4 (5d).

Embodiment

The present invention relates to the new compound of a class, it is based on quinazolinone structure parent nucleus, and is the conditioning agent of mitotic kinesins.By inhibition or adjusting mitotic kinesins, but not other kinesin (as the transhipment kinesin), can realize the specific inhibitory effect of on cell proliferation.Therefore, the present invention has utilized following discovery exactly: the function of interference mitotic kinesins can cause the deformity or the dysfunction of mitotic spindle, causes the cell cycle to be stopped and necrocytosis usually.The method that suppresses people KSP kinesin comprises makes that inhibitor of the present invention contacts with the KSP kinesin, people KSP kinesin particularly, comprises fragment and the variant of KSP.This restraining effect can be that the ATP hydrolytic activity of KSP kinesin and/or mitotic spindle form in the activity, makes mitotic spindle destroyed.The reduction division spindle body also can be destroyed.

The objective of the invention is to develop inhibitor and the conditioning agent of mitotic kinesins, particularly KSP, with treatment and cel l proliferation diseases associated.Traditionally, the huge raising in cancer (a kind of cell proliferation disorders) treatment is relevant with the therapeutical agent that identifies by new mechanism effect.As if this example wherein not only comprises the Taxan that microtubule is formed the generation effect, but also comprises the camptothecine as the topoisomerase I inhibitor.The difference of Compounds and methods for of the present invention is their selectivity, and is preferred for treating the disease of proliferative cell, includes but not limited to cancer, hyperplasia, restenosis, megalocardia, Immunological diseases and inflammation.

Therefore, the present invention relates to use method with the Quinazol derivative of following formula,

The quinazolinone acid amides of formula 1a:

The quinazolinone sulphonamide of formula 1b:

The quinazoline ketoamine of formula 1c and 1d:

Wherein:

R ₁Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₂And R ₂' be independently selected from hydrogen, alkyl, oxa alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl; Perhaps R ₂And R ₂' form 3-7 unit together to encircle;

R ₃Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl, oxa alkyl, oxa alkyl aryl, replace oxa alkyl aryl, R ₁₅O-and R ₁₅-NH-;

R ₃' be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl and R ₁₅-NH-;

R ₃" be selected from alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₄Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl and R ₁₆-alkylidene group;

R ₅, R ₆, R ₇And R ₈Be independently selected from hydrogen, alkyl, alkoxyl group, halogen, fluoro-alkyl, nitro, dialkyl amido, alkyl sulphonyl, alkylsulfamoyl group, sulfamoyl alkyl, sulfamyl aryl, alkylthio, carboxyalkyl, carboxamide groups, aminocarboxyl, aryl and heteroaryl;

R ₁₅Be selected from alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₁₆Be selected from alkoxyl group, amino, alkylamino, dialkyl amido, N-heterocyclic radical and replace the N-heterocyclic radical.

All above compounds all can be used as the kinesin inhibitor, but not all compound all is new.Particularly, some urea is (as R wherein ₃Be R ₁₅The compound of-NH) is disclosed in the 5th, 756, No. 502 United States Patent (USP)s as the medicine that changes the cholecystokinin effect.Though concrete exception has reflected that it is the part of notion of the present invention that the applicant wishes to avoid claimed those in claims on function, theme that can not granted patent owing to be not related to scope of the present invention.

Definition

Alkyl comprises linearity, branch or cyclic hydrocarbon structures and their combination.Low alkyl group is meant the alkyl with 1-5 carbon atom.The example of low alkyl group comprises methyl, ethyl, propyl group, sec.-propyl, butyl, sec-butyl and the tertiary butyl etc.Preferred alkyl is C ₂₀The perhaps alkyl of even lower level.Preferred alkyl is C ₁₃The perhaps alkyl of even lower level.Cycloalkyl is the following notion of alkyl, and comprises the cyclic hydrocarbon group of 3-13 carbon atom.The example of cycloalkyl comprises cyclopropyl, cyclobutyl, cyclopentyl, norcamphyl, adamantyl etc.In the present invention, alkyl is meant alkyl group, alkenyl and alkynyl group, and it comprises cyclohexyl methyl, vinyl, allyl group, prenyl etc.Alkylidene group is meant identical with alkyl but the group of two tie points is arranged.The example of alkylidene group comprises ethylidene (CH ₂CH ₂-), trimethylene (CH ₂CH ₂CH ₂-), dimethyl-trimethylene (CH ₂C (CH ₃) ₂CH ₂-) and cyclohexyl-trimethylene (CH ₂CH ₂CH (C ₆H ₁₃)-).When alkyl has the carbon atom of concrete number, also comprise all geometrical isomers with similar number carbon atom; Therefore, for example " butyl " just comprises normal-butyl, sec-butyl, isobutyl-and the tertiary butyl; " propyl group " comprises n-propyl and sec.-propyl.

Alkoxyl group is meant by Sauerstoffatom and is connected on the precursor structure and has straight chain, side chain or the cyclic configuration of 1-8 carbon atom and their combination.Its example comprises methoxyl group, oxyethyl group, isopropoxy, cyclopropyl oxygen base, cyclohexyl oxygen base etc.Lower alkoxy is meant the group that comprises 1-4 carbon atom.

Acyl group is meant by the carbonyl functional group and is connected on the precursor structure and has straight chain, side chain or the cyclic configuration of 1-8 carbon atom and their combination, can be saturated, unsaturated and aromaticity.One or more carbon atom in the acyl group can be by nitrogen, oxygen or sulphur displacement, if with the tie point of precursor structure be carbonyl.Its example comprises ethanoyl, benzoyl, propionyl, isobutyryl, tert-butoxycarbonyl, benzyl oxygen base carbonyl etc.Lower acyl is meant the acyl group that comprises 1-4 carbon atom.

Aryl and heteroaryl are meant and comprise 0-3 heteroatomic 5-6 unit's aromatic nucleus or assorted aromatic nucleus that is selected from O, N or S; Comprise 0-3 heteroatomic 9-10 fragrant ring system of unit's two cyclophanes or assorted aromatic ring that is selected from O, N or S; Perhaps comprise 0-3 13-14 unit's tricyclic aromatic ring system or assorted aromatic ring that is selected from O, N or S.6-14 unit aromatic carbocyclic ring system comprises benzene, naphthalene, indane, 1,2,3,4-tetralin and fluorenes etc.The 5-10 membered aromatic heterocycle comprises for example imidazoles, pyridine, indoles, thiophene, benzopyrone, thiazole, furans, benzoglyoxaline, quinoline, isoquinoline 99.9, quinoxaline, pyrimidine, pyrazine, tetrazolium and pyrazoles.

Alkylaryl is meant that aryl wherein is connected group on the precursor structure by alkyl.Its example comprises benzyl, styroyl, phenyl vinyl, phenyl allyl group etc.Oxa alkyl and oxa alkyl aryl are meant that one or more methylene radical is by oxygen metathetical alkyl and alkylaryl.The example of oxa alkyl and oxa alkyl aryl comprises ethoxy ethoxy ethyl (3,6-two oxa-octyl groups), benzyloxymethyl and phenoxymethyl; Generally, glycol ethers such as polyoxyethylene glycol are also included within the scope of this group.Miscellaneous alkyl aryl is meant that heteroaryl wherein is connected group on the precursor structure by alkyl.Its example comprises furyl methyl, pyridylmethyl, Pyrimidylmethyl etc.

Heterocycle is meant that wherein 1-4 carbon atom is by heteroatoms metathetical cycloalkyl or aryl such as oxygen, nitrogen or sulphur.The heterocyclic example that comprises in the scope of the invention is tetrahydroglyoxaline, tetramethyleneimine, pyrazoles, pyrroles, indoles, quinoline, isoquinoline 99.9, tetrahydroisoquinoline, cumarone, benzdioxan, benzo dioxole (when as substituting group, being commonly referred to methylenedioxyphenyl), tetrazolium, morpholine, thiazole, pyridine, pyrazine, pyrimidine, thiophene, furans, oxazole, oxazoline, isoxzzole, dioxan, tetrahydrofuran (THF) etc." N-heterocyclic radical " is meant the heterocyclic substituent that comprises nitrogen-atoms.The term heterocyclic radical comprises heteroaryl, and it is the subordinate concept of heterocyclic radical.The example of N-heterocyclic radical comprises 4-morpholinyl, 4-thio-morpholinyl, piperidino, 1-pyrrolidyl, 3-thiazolidyl, piperazinyl and 4-(3,4-dihydrobenzo oxazines base).The example of substituted heterocyclic radical comprises 4-methyl isophthalic acid-piperazinyl and 4-benzyl-piperidino.

Substituted alkyl; aryl and heteroaryl are meant the alkyl that hydrogen atom is wherein replaced by following group; aryl or heteroaryl: alkyl; halogen; hydroxyl; alkoxyl group; alkylenedioxy group (as methylene-dioxy); fluoroalkyl; carboxyl (COOH); alkane carbonyl oxygen base (as acyloxy RCOO-); carboxyalkyl (COOR); carboxamide groups; sulfamoyl alkyl; the sulfamyl aryl; aminocarboxyl; benzyloxycarbonyl amino (CBZ-amino); cyano group; carbonyl; nitro; dialkyl amido; alkylamino; amino; alkylthio; the alkyl sulfinyl; alkyl sulphonyl; alkylsulfamoyl group; artyl sulfo; the aryl sulfinyl; aryl sulfonyl; amidino groups; phenyl; benzyl; heteroaryl; heterocyclic radical; phenoxy group; benzyloxy; perhaps heteroaryl oxygen base.For the present invention, substituted alkyl also comprises oxa alkyl, as one or more carbon by oxygen metathetical alkyl.

Halogen is meant fluorine, chlorine, bromine or iodine.Fluorine, chlorine and bromine are preferred.Dihalo aryl, dihalo alkyl, three halogenated aryls etc. are meant aryl and the alkyl that is replaced by a plurality of but not necessarily identical halogen, and therefore, 4-chloro-3-fluorophenyl is also in the scope of dihalo aryl.

Compound great majority of the present invention all comprise one or more asymmetric center and (as are connected R ₂And R ₂' on carbon atom), and can produce enantiomorph, diastereomer and can be thus according to other stereoisomer forms of absolute stereo chemistry definition, as (R)-or (S)-.The present invention includes all possible isomer, comprise racemic mixture, optical purity form and intermediate mixture.Opticity (R)-and (S)-isomer can prepare by using chiral synthon or chiral reagent, perhaps by using routine techniques to split.When compound of the present invention comprised olefinic double bond or other how much asymmetry centers, except as otherwise noted, compound of the present invention should comprise E and Z geometrical isomer.Equally, all tautomers are also included within the scope of the present invention.

When needs, R-and S-isomer can split by method known to those skilled in the art, but for example form the diastereomeric salt or the complex compound that can for example pass through Crystallization Separation; Formation can be for example by the isolating diastereomer derivative of crystallization, solution-air or liquid phase chromatography; The selective reaction of a kind of enantiomorph and enantiomorph specific reagent, for example oxydasis or reduction reaction are separated modification or unmodified enantiomorph then; Chiral environment as chiral support (as with chiral ligand bonded silica gel) go up or in the presence of chiral solvent with solution-air or liquid phase chromatography.Be understandable that when by one of aforesaid separation method needed enantiomorph being converted into other chemical substances, the step that might need other is to discharge desirable enantiomeric form.Perhaps, synthetic by the asymmetry of using optically-active reagent, substrate, catalyzer or solvent, perhaps a kind of enantiomorph is converted into another kind of enantiomorph by asymmetric conversion, can synthesize the specificity enantiomorph.Carrying out the synthetic example by the opticity initiator is shown among Fig. 4.

In one embodiment, it will be appreciated by those skilled in the art that two adjacent R ²Group can condense and form ring structure together.And the condensed ring structure can comprise heteroatoms, and can be replaced by one or more substituting group " R ".It should be noted that in addition for cycloalkyl (as saturated ring structure), each position can comprise two substituting groups--R and R '.

For structure 1a, 1b, 1c and 1d, but mainly be 1a, in preferred embodiments, R ₁Be selected from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl and substituted alkyl aryl.

In a more preferred embodiment, R ₁Be selected from low alkyl group, benzyl, substituted benzyl, phenyl, naphthyl and the substituted-phenyl of hydrogen, low alkyl group, replacement.

In the most preferred embodiment, R ₁Be selected from hydrogen, ethyl, propyl group, methoxy ethyl, naphthyl, phenyl, bromophenyl, chloro-phenyl-, p-methoxy-phenyl, ethoxyl phenenyl, tolyl, 3,5-dimethylphenyl, chlorofluorobenzene base, methyl chloride phenyl, ethylphenyl, styroyl, benzyl, benzyl chloride base, methyl-benzyl, methoxy-benzyl, cyano group benzyl, hydroxybenzyl, tetrahydrofuran (THF) ylmethyl and (ethoxy carbonyl) ethyl.

In preferred embodiments, R ₂Be selected from hydrogen, alkyl or substituted alkyl.It will be understood by those skilled in the art that structure 1a, 1b, 1c and 1d are at R ₂The carbon atom place that is connected has the potential chiral centre.Therefore, R ₂The position can comprise two substituent R ₂And R ₂'.R ₂And R ₂' group can be identical or different; If different, then compound is a chirality.Work as R ₂And R ₂' not simultaneously, embodiment preferred is only utilized single non-hydrogen R ₂The present invention includes and use the pure enantiomorph and the mixture of enantiomorph, comprise racemic mixture, also is preferred but use optically pure basically enantiomorph in normal circumstances.

In a more preferred embodiment, R ₂Be selected from the low alkyl group of hydrogen, low alkyl group and replacement, and R ₂' be hydrogen.In a more preferred embodiment, R ₂Be selected from hydrogen, methyl, ethyl, propyl group, methylmercaptoethyl, amino butyl, (CBZ) amino butyl, cyclohexyl methyl, benzyloxymethyl, methyl sulfinyl ethyl, methyl sulfinyl methyl, methylol, benzyl and indyl methyl.

In preferred embodiments, R ₃Be selected from alkyl, substituted alkyl, alkylaryl, heteroaryl, aryl, substituted aryl, replacement oxa alkyl aryl, R ₁₅O-and R ₁₅-NH-, and R ₁₅Be selected from alkyl, aryl and substituted aryl.

In a more preferred embodiment, if R ₃Not R ₁₅NH, then R ₃Be selected from C ₁-C ₁₃Alkyl; The low alkyl group that replaces; Phenyl; Naphthyl; By the phenyl of one or more halogen, low alkyl group, lower alkoxy, nitro, carboxyl, methylene-dioxy or trifluoromethyl replacement; Xenyl; Benzyl; Phenoxymethyl; The halogenated phenoxy methyl; Phenyl vinyl; Heteroaryl; The heteroaryl that is replaced by low alkyl group; And benzyloxymethyl.

In the most preferred embodiment, if R ₃Not R ₁₅NH, then R ₃Be selected from ethyl; propyl group; chloropropyl; butoxy; heptyl; butyl; octyl group; tridecyl; (ethoxy carbonyl) ethyl; dimethyl aminoethyl; dimethylaminomethyl; phenyl; naphthyl; halogenophenyl; dihalogenated phenyl; cyano-phenyl; halogen (trifluoromethyl) phenyl; the chlorophenoxy methyl; p-methoxy-phenyl; carboxyl phenyl; ethylphenyl; tolyl; xenyl; methylenedioxyphenyl; the methyl sulphonyl phenyl; the methoxychlor phenyl; chloronaphthyl, methylnaphthyl; methyl halogenated phenyl; trifluoromethyl; butyl phenyl; the amyl group phenyl; the methyl nitrophenyl; phenoxymethyl; Dimethoxyphenyl; styryl; the nitroxyl chloride phenyl; nitrophenyl; dinitrophenyl; two (trifluoromethyl) phenyl; benzyloxymethyl; benzyl; furyl; benzofuryl; pyridyl; indyl; picolyl; picolyl; quinolyl; pyrazolyl; and imidazolyl.

In a more preferred embodiment, if R ₃Be R ₁₅NH, then R ₁₅Be selected from low alkyl group; Cyclohexyl; Phenyl; And by the phenyl of halogen, low alkyl group, lower alkoxy or lower alkylthio replacement.

In the most preferred embodiment, if R ₃Be R ₁₅NH, then R ₁₅Be sec.-propyl, butyl, cyclohexyl, phenyl, bromophenyl, dichlorophenyl, p-methoxy-phenyl, ethylphenyl, tolyl, trifluoromethyl or methylthio group phenyl.

In preferred embodiments, R ₄Be selected from alkyl, aryl, alkylaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl and R ₁₆-alkylidene group, and R ₁₆Be selected from alkoxyl group, amino, alkylamino, dialkyl amido and N-heterocyclic radical.

In a more preferred embodiment, R ₄Be selected from low alkyl group, the cyclohexyl of low alkyl group, replacement; By the phenyl of hydroxyl, lower alkoxy or low alkyl group replacement; Benzyl; The heteroaryl methyl; The heteroaryl ethyl; Heteroaryl propyl group and R ₁₆-alkylidene group, wherein R ₁₆Be amino, low-grade alkyl amino, two (low alkyl group) amino, lower alkoxy or N-heterocyclic radical.

In the most preferred embodiment, R ₄Be selected from methyl, ethyl, propyl group, butyl, cyclohexyl, carboxy ethyl, the carboxyl methyl, methoxy ethyl, hydroxyethyl, hydroxypropyl, dimethyl aminoethyl, dimethylaminopropyl, the diethylamino ethyl, the diethylamino propyl group, aminopropyl, the methylamino propyl group, 2,2-dimethyl-3-(dimethylamino) propyl group, 1-cyclohexyl-4-(diethylamino) butyl, amino-ethyl, amino butyl, amino amyl group, amino hexyl, the amino ethoxy ethyl, the sec.-propyl aminopropyl, the diisopropylaminoethyl ethyl, 1-methyl-4-(diethylamino) butyl, (t-Boc) aminopropyl, hydroxy phenyl, benzyl, p-methoxy-phenyl, methyl methoxy base phenyl, 3,5-dimethylphenyl, tolyl, ethylphenyl, (oxo-pyrrolidine base) propyl group, (methoxycarbonyl) ethyl, the benzyl piepridine base, the pyridyl ethyl, pyridylmethyl, the morpholinyl ethyl, morpholinyl propyl, piperidyl, the azetidine ylmethyl, the azetidinyl propyl group, the pyrrolidyl ethyl, the pyrrolidyl propyl group, piperidino methyl, the piperidyl ethyl, the imidazolyl propyl group, the imidazolyl ethyl, (N-ethyl pyrrole N-alkyl) methyl, (methylpyrrole alkyl) ethyl, (methylpyrrole alkyl) propyl group, (methylpiperazine base) propyl group, furyl methyl and indyl ethyl.

In another preferred embodiment, R ₅Be hydrogen or halogen; R ₆Be hydrogen, methyl or halogen; R ₇Be hydrogen, halogen, methyl or trifluoromethyl; And R ₈Be hydrogen or halogen.

In particularly preferred embodiments, R ₁Be benzyl or halogeno-benzyl; R ₂Be selected from ethyl and propyl group; R ₂' be hydrogen; R ₃It is substituted-phenyl; R ₃' be substituted-phenyl; R ₃" be substituted-phenyl; R ₄Be-(CH) _mOH or-(CH ₂) _pR ₁₆, m is 2 or 3, p is 1-3; R ₅Be hydrogen; R ₆Be hydrogen; R ₇It is halogen; R ₈Be hydrogen; And R ₁₆Be selected from amino, propyl group amino and azetidinyl.

When the sulphonamide of main consideration structure 1b, R ₁Be preferably selected from low alkyl group, benzyl, substituted benzyl, phenyl and substituted-phenyl in hydrogen, low alkyl group, replacement; R ₂Be selected from hydrogen and low alkyl group, and R ₂' be hydrogen; R ₃' be selected from C ₁-C ₁₃Alkyl, phenyl, naphthyl, the phenyl, xenyl and the heteroaryl that are replaced by halogen, low alkyl group, lower alkoxy, nitro, methylene-dioxy or trifluoromethyl; And R ₄The phenyl, benzyl, heteroaryl methyl, heteroaryl ethyl, heteroaryl propyl group, heteroaryl ethyl, heteroaryl propyl group and the R that are selected from low alkyl group, cyclohexyl, are replaced by hydroxyl, lower alkoxy or low alkyl group ₁₆-alkylidene group, wherein R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, lower alkoxy or N-heterocyclic radical, particularly pyrrolidyl, piperidyl or imidazolyl.

When the sulphonamide of main consideration structure 1b, R ₁Most preferably be selected from low alkyl group, benzyl, substituted benzyl and substituted-phenyl; R ₂Be hydrogen or low alkyl group; R ₂' be hydrogen; R ₃Be selected from substituted-phenyl and naphthyl; R ₄Be R ₁₆-alkylidene group; R ₇Be hydrogen, fluorine, methyl or chlorine; R ₅, R ₆And R ₈Be hydrogen; And R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, pyrrolidyl, piperidyl, imidazolyl and morpholinyl.

When the amine of main consideration structure 1c and 1d, R ₁Be preferably selected from low alkyl group, benzyl, substituted benzyl, phenyl, naphthyl and substituted-phenyl in hydrogen, low alkyl group, replacement; R ₂Be selected from the low alkyl group of hydrogen, low alkyl group and replacement; R ₂' be hydrogen; R ₃" be selected from C ₁-C ₁₃The low alkyl group of alkyl, replacement, phenyl, naphthyl, the phenyl, xenyl, benzyl and the heterocyclic radical that are replaced by halogen, low alkyl group, lower alkoxy, nitro, methylene-dioxy or trifluoromethyl; And R ₄The phenyl, benzyl, substituted benzyl, heterocyclic radical, heteroaryl methyl, heteroaryl ethyl, heteroaryl propyl group and the R that are selected from low alkyl group, cyclohexyl, are replaced by hydroxyl, lower alkoxy or low alkyl group ₁₆-alkylidene group, wherein R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, lower alkoxy or N-heterocyclic radical.

When the amine of main consideration structure 1c and 1d, R ₁Most preferably be selected from low alkyl group, benzyl, substituted benzyl and substituted-phenyl; R ₂Be hydrogen or low alkyl group; R ₂' be hydrogen; R ₃" be selected from substituted-phenyl, heterocyclic radical and naphthyl; R ₄Be selected from substituted benzyl, heterocyclic radical and R ₁₆-alkylidene group; R ₆And R ₇Be selected from hydrogen and halogen; R ₅And R ₈Be hydrogen; And R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, pyrrolidyl, piperidyl, imidazolyl and morpholinyl.When there being R ₃" when (as in 1d), it most preferably is selected from halogenophenyl, phenyl polyhalide base, tolyl, 3,5-dimethylphenyl, p-methoxy-phenyl, Dimethoxyphenyl, cyano-phenyl, trifluoromethyl, Trifluoromethoxyphen-l, two (trifluoromethyl) phenyl, carboxyl phenyl, tert-butyl-phenyl, methoxycarbonyl phenyl, piperidyl and naphthyl.

Compound of the present invention synthesizes as shown below, wherein uses method known to those skilled in the art.For example; people such as Ager; the method of describing among the J.of Med.Chem., 20:379-386 (1977) (document is incorporated herein by reference at this), quianzolinones can obtain by the acid catalysis condensation reaction of N-acyl group anthranilic acid and aromatic primary amine.The additive method of preparation quianzolinones is described in the 5th, 783, and 577,5,922,866 and 5,187, in No. 167 United States Patent (USP)s, the content of these documents is incorporated herein by reference at this.

Compound of the present invention can the method as shown in Fig. 1,2,4 and 5 prepare.The compound of formula 1d is according to the method preparation that is similar among Fig. 1, but in the end the carboxylic acid halides of step is replaced with alkyl halide.

After the preparation, compound of the present invention can be used in the various application.It will be appreciated by persons skilled in the art that mitotic division can change by several different methods; That is to say, can change by the activity that increases or reduce the component in the mitotic division approach.Different is that mitotic division can be by suppressing or activate some component to disturb its balance to influence (as destroyed).Similarly method also can be used for changing reduction division.

In preferred embodiments, compound of the present invention is used to regulate the formation of mitotic spindle, causes prolonging in the mitotic division cell cycle thus to stop.Be meant the formation that changes mitotic spindle at this used term " adjusting ", comprise the formation that increases or reduce spindle body.Be meant by mitotic kinesins at this used term " formation of mitotic spindle " microtubule is combined into dipolar configuration.Be meant that at this used term " mitotic spindle dysfunction " mitotic division stops or forming monopolar spindle.

Compound of the present invention can be used for and mitotic kinesins--and KSP combines and/or regulates its activity.In preferred embodiments, KSP is people KSP, but also can use the KSP kinesin that derives from the other biological body.In the present invention, " adjusting " is meant that increasing or reduce spindle pole separates, and causes the deformity (as opening) of mitotic division spindle pole, perhaps mitotic spindle produced form and disturbs.For this purpose, the variant and/or the fragment that also comprise KSP in the definition of KSP.(application number is 09/428 referring to the U.S. Patent application of submitting on October 27th, 1999 " Methods of Screening forModulators of Cell Proliferation and Methods of Diagnosing Cell ProliferationStates (method of screening cell proliferation conditioning agent and the method for diagnosis cell vegetative state) ", 156), its content is incorporated herein by reference at this.In addition, also can use other mitotic kinesins in the present invention.Yet compound of the present invention has specificity for KSP.

In active testing, KSP or compound of the present invention are non-can to be combined on the insoluble carrier diffusely, and this carrier has sample region of acceptance (as microtiter plate, array (array) etc.) separately.Insoluble carrier can be made in conjunction with material thereon by any compound of the present invention, is easy to separate with soluble material, perhaps matches with total screening method.The surface of these carriers can be a solid or porous, and can be Any shape.The example of suitable insoluble carrier comprises microtiter plate, array, film and pearl.These materials are normally by glass, plastics (as polystyrene), polysaccharide, nylon or Nitrocellulose, Teflon ^TMDeng making.Microtiter plate and array are especially easily, because use a spot of reagent and sample can carry out a large amount of tests simultaneously.The concrete combination of The compounds of this invention is not critical, needs only itself and reagent and total method of the present invention and is complementary, and keeps the active of compound and can not spread getting final product.Preferred combining method comprises that use antibody is (when protein bound is on carrier, it can three-dimensional ground block ligand binding site or activation sequences), directly be combined on " viscosity " or the ionophore chemically crosslinked, synthetic protein or medicine etc. from the teeth outwards.Behind conjugated protein or medicine, remove excessive not bond material by washing.The sample region of acceptance then can be by being blocked with bovine serum albumin (BSA), casein or other inoculation albumen or the insulation of other materials.

Antimitotic agent of the present invention can use separately to regulate the activity of mitotic kinesins, particularly KSP.In this embodiment, mitogenic agent of the present invention mixes with KSP, analyzes the activity of KSP then.The kinesin activity is well known in the art, and comprises one or more kinesin activity.The kinesin activity comprises the ability that influences the ATP hydrolysis; The microtubule combination; Slide and polymerization/depolymerization (to the microtubule effect of kinetics); With other combination of proteins of spindle body; With the protein bound that relates in the cell cycle control; Substrate as other enzymes; As kinases or proteolytic enzyme; And specific kinesin cytoactive such as spindle pole separate.

The method of analyzing is well-known (for example referring to people such as Hall (1996), Biophys.J., 71:3467-3476 to those skilled in the art; People such as Turner, 1996, AnalBiochem.242 (1): 20-5; People such as Gittes, 1996, Biophys.J.70 (1): 418-29; People such as Shirakawa, 1995, J.Exp.Biol 198:1809-15; People such as Winkelmann, 1995, Biophys.J.68:2444-53; People such as Winkelmann, 1995, Biophys.J.68:72S).

Also can use the active method of mensuration ATP enzymic hydrolysis as known in the art.Preferably, use is based on the experiment of solution.In the 09/314th, No. 464 U.S. Patent application (its content is incorporated herein by reference at this) that on May 18th, 1999 submitted these experiments have been described.Perhaps, use conventional method.For example, can be to the P in the kinesin _iRelease is carried out quantitatively.In a preferred embodiment, ATP enzymic hydrolysis activity experiment uses PCA (perchloric acid) and the Victoria Green WPB reagent (the sour sodium of 8.27mM molybdenum (II), the Victoria Green WPB oxalate of 0.33mM and the TritonX-100 of 0.8mM) of 0.3M.When carrying out this experiment, the cancellation in the cold 0.3M PCA of 90 μ l of the reactant of 10 μ l.Use the phosphoric acid salt standard substance, so can be the inorganic phosphate that mM discharged with data conversion.When all reactants and standard substance all during cancellation, add the Victoria Green WPB reagent of 100 μ l in the associated orifices of for example microtiter plate in PCA.Make mixture colour developing 10-15 minute, read the absorbancy of plate then at the 650nm place.If use the phosphoric acid salt standard substance, then the absorbancy reading can be converted into mM P _i, and the relative time mapping.In addition, ATP enzyme experiment as known in the art comprises the luciferase experiment.

The atpase activity of kinesin motion field also can be used for monitoring the effect of conditioning agent.In one embodiment, do not having to carry out the experiment of kinesin ATP enzyme in the presence of the microtubule.In another embodiment, when having microtubule to exist, carry out the experiment of ATP enzyme.In above-mentioned experiment, can detect dissimilar conditioning agents.The effect of conditioning agent does not rely on the concentration of microtubule and ATP in preferred embodiments.In another embodiment, by increasing ATP, microtubule or the two concentration, can reduce the effect of conditioning agent to kinesin ATP enzyme.In another embodiment,, can increase the effect of conditioning agent by increasing ATP, microtubule or the two concentration.

The medicine of the biochemical activity of external adjusting KSP can be followed in vivo and screen.These medicines screening method in vivo comprises the experiment of existence, form, activity, distribution or the amount of relevant cell cycle distribution, cell survival rate or mitotic spindle.For example the method by the distribution of wandering cells meter monitoring cell quantity in the cell cycle is known for those skilled in the art, and the method for measuring cell survival rate also is like this.For example (application number is 09/428 referring to: the U.S. Patent application of submitting on October 27th, 1999 " Methods of Screening for Modulators of Cell Proliferation andMethods of Diagnosing Cell Proliferation States (method of screening cell proliferation conditioning agent and the method for diagnosis cell vegetative state) ", 156), its content is incorporated herein by reference at this.

Except that aforesaid experiment, the monitoring formation of spindle body and odd-shaped microscopy also are known (for example referring to Whitehead and Rattner (1998), J.Cell Sci.111:2551-61 for those skilled in the art; People such as Galgio, (1996) J.Cell Biol., 135:399-414).

Compound of the present invention suppresses the KSP kinesin.Inhibiting one to measure be IC ₅₀, its activity that is defined as KSP is lowered 50% o'clock compound concentration.The IC of compound ₅₀Preferably be lower than about 1mM, in preferred embodiments, IC ₅₀Be lower than about 100 μ M, in a more preferred embodiment, IC ₅₀Be lower than about 10 μ M, in particularly preferred embodiments, IC ₅₀Be lower than about 1 μ M, in embodiment preferred particularly, IC ₅₀Be lower than about 100nM, and in the most preferred embodiment, IC ₅₀Be lower than about 10nM.IC ₅₀Measurement carry out with ATP enzyme experiment.

It is K that inhibiting another measured _iFor IC ₅₀Be lower than the compound of 1 μ M, K _iPerhaps K _dBe defined as the interactional dissociation constant of quinazolinone and KSP.Preferred compound has the K that is lower than about 100 μ M _i, in preferred embodiments, K _iBe lower than about 10 μ M, in a more preferred embodiment, K _iBe lower than about 1 μ M, in particularly preferred embodiments, K _iBe lower than about 100nM, and in the most preferred embodiment, K _iBe lower than about 10nM.The K of compound _iBe by IC according to three hypothesis ₅₀Measure.The first, only a compound molecule is combined on the enzyme, and does not have cooperative.The second, the concentration of organized enzyme and test compounds are known (impurity or the inactivation forms that for example, do not have significant quantity in preparation).The 3rd, the enzymatic speed of enzyme-inhibitor complex is zero.The data fitting of speed (being compound concentration) is in following equation:

$V=V_{\max }{E}_0[1-\frac{({\mathrm{<figure-callout\; id="0"\; label="E"\; filenames="A20081008341301051.png,A20081008341301101.png"\; state="\{\{state\}\}">E</figure-callout>}}_0+I_0+\mathrm{Kd})-\sqrt{{({\mathrm{<figure-callout\; id="0"\; label="E"\; filenames="A20081008341301051.png,A20081008341301101.png"\; state="\{\{state\}\}">E</figure-callout>}}_0+I_0+\mathrm{Kd})}^2-4E_0{I}_0}}{2E_0}]$

Wherein: V observes speed, V _MaxBe the speed of resolvase, I ₀Be inhibitor concentration, E ₀Be enzyme concn, and K _dIt is the dissociation constant of enzyme-inhibitor complex.

Inhibiting another to measure be GI ₅₀, it is defined as the compound concentration that cell growth rate reduces at 50% o'clock.Preferred compound has the GI that is lower than about 1mM ₅₀The preference of compound is along with GI ₅₀And change: GI ₅₀The compound that is lower than about 20 μ M is preferred, GI ₅₀For the compound of about 10 μ M is preferred, GI ₅₀The compound that is lower than about 1 μ M is preferred, GI ₅₀For the compound of about 100nM is preferred, GI ₅₀The compound that is lower than about 10nM is preferred.GI ₅₀Measure by using cell proliferation experiment.

Compound of the present invention is used for the treatment of cell proliferation disorders.The morbid state of available method and composition treatment of the present invention includes but not limited to the proliferation function that cancer (further as described below), autoimmune disease, sacroiliitis, transplant rejection, inflammatory bowel disease, medical procedure (including but not limited to operation, angioplasty etc.) bring out.Be understandable that in some cases, cell might be in high or low vegetative state (error state (ERST)), and still need treatment.For example, during wound healing, cell might " normally " be bred, but wishes to strengthen this proliferation function.Similarly, as discussed above, at agriculture field, cell might be in " normally " state, but wish growth or plant that passes through inhibition negative impact crop or the growth of organism, regulate proliferation function, to promote the growth of crop by directly strengthening crop.Therefore, in one embodiment, the present invention includes the cell that is applied to suffer from one of these diseases or individual or prevent that it from suffering from one of these diseases.

Compounds and methods for of the present invention is considered to useful especially for the treatment cancer, comprises solid tumor, as skin, mammary gland, brain, cervical cancer, carcinoma of testis etc.More specifically, the cancer of available composition of the present invention and method treatment includes but not limited to: The heart: sarcoma (angiosarcoma, fibrosarcoma, rhabdosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, do not break up minicell, do not break up maxicell, gland cancer), alveolar (bronchiole) cancer, bronchial adenoma, sarcoma, lymphoma, cartilage progonoma, mesothelioma; Stomach Enteron aisle: oesophagus (squamous cell carcinoma, gland cancer, leiomyosarcoma, lymphoma), stomach (cancer, lymphoma, leiomyosarcoma), pancreas (ductal pancreatic adenocarcinoma, nesidioblastoma, glucagonoma, gastrinoma, carcinoid tumor, Vipoma), small intestine (gland cancer, lymphoma, carcinoid tumor, kaposi's sarcoma, leiomyoma, vascular tumor, lipoma, neurofibroma, fibroma), large intestine (gland cancer, pipe adenoma, fine hair adenoma, progonoma, leiomyoma); Genitourinary tract: kidney (gland cancer, wilms' tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transition cell cancer, gland cancer), prostate gland (gland cancer, sarcoma), testis (spermocytoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, mesenchymal cell cancer, fibroma, fibroadenoma, adenoma sample tumour, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, adenoma, vascular tumor; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple spinal cord knurl, pernicious giant cells tumour chordoma, chondrosteoma (osteocartilaginous exostosis), optimum chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma and giant cells tumour; Neural system: skull (osteoma, vascular tumor, granuloma, vitiligoidea, osteitis deformans), meninx (meningioma, meningosarcoma, neurogliosis), brain (astrocytoma, medulloblastoma, neurospongioma, chamber tuberculation, germinoma [pinealoma], glioblastoma multiforme, Oligodendroglioma, schwannoma, retinoblastoma, congenital tumor), notochord (neurofibroma, meningioma, neurospongioma, sarcoma); Gynaecology: uterus (uterus meninx cancer), uterine cervix (uterine cervix heteroplasia before cervical cancer, the tumour), ovary (ovarian cancer [serocyst gland cancer, pseudomucinous cystadenocarcinoma, non-classified cancer], granulosa-theca cell tumour, Sai Ertuoli-Leydig cell tumour, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, gland cancer, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, grape bunch shape sarcoma [embryonal rhabdomyosarcoma]), uterine tube (cancer); Blood: blood (myelocyte sample leukemia [acute and chronic], acute lymphoblastic leukemia, lymphocytic leukemia, marrow and bone marrow proliferative disease, multiple myeloma, myelodysplasia syndromes), Hodgkin, non Hodgkin lymphoma [malignant lymphoma]; Skin: malignant melanoma, rodent cancer, squamous cell carcinoma, kaposi's sarcoma, mole dysplastic nevus, lipoma, vascular tumor, dermatofibroma, keloid, psoriasis; And Body of gland: neuroblastoma.Therefore, comprise the cell that is subjected to any aforesaid illness influence at this used term " cancer cells ".

Therefore, composition of the present invention can deliver medicine to cell.Term " administration " is the mitogenic agent of the present invention that points to the cell drug treatment significant quantity among cell culture medium and the patient.Term " treatment significant quantity " is meant can be to the dosage of the individual generation effect of administration.Accurate dose depends on therapeutic purpose, and can be determined by known method by those skilled in the art.Well-known in the artly be, must be according to whole body and topical, age, body weight, total healthy state, sex, diet, administration time, the interaction of medicine and the severity of disease, dosage is adjusted, and can be determined with conventional experiment by those skilled in the art.Be meant at this used term " cell " and can change wherein mitotic division or maiotic almost most any cell.

In the present invention, " patient " comprises people and other animals (particularly Mammals) and other biological body.Therefore, method of the present invention can be applicable in people's the treatment and veterinary applications.In preferred embodiments, the patient is a Mammals, and in the most preferred embodiment, the patient is the people.

Mitogenic agent with desirable pharmacologically active can deliver medicine to the patient with physiologically acceptable carrier.According to the mode of introducing, compound of the present invention can several different methods as described below be prepared.The concentration of therapeutical active compound in preparation can be 0.1-100 weight %.Medicine can carry out separately or with other treatment (as radiotherapy) or other chemotherapeutics.

In preferred embodiments, pharmaceutical composition is water miscible form, and as acceptable salt on the pharmacology, this comprises the bronsted lowry acids and bases bronsted lowry additive salt.Those salt that " acceptable acid salt on the pharmacology " is meant the biological effectiveness that still keeps free alkali, forms with mineral acid or organic acid, described mineral acid for example is hydrochloric acid, Hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid etc., and organic acid for example is acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, toxilic acid, propanedioic acid, succsinic acid, fumaric acid, tartrate, citric acid, phenylformic acid, styracin, amygdalic acid, methylsulfonic acid, ethyl sulfonic acid, tosic acid, Whitfield's ointment etc." acceptable base addition salt on the pharmacology " comprises the salt that is derived from mineral alkali, for example is sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminium salt etc.Particularly preferably be ammonium, potassium, sodium, calcium and magnesium salts.Be derived from the salt that the salt of acceptable organic non-toxic bases on the pharmacology comprises primary amine, secondary amine, tertiary amine, replacement amine (amine that comprises natural replacement), cyclic amine and deacidite, these organic basess for example are isopropylamine, Trimethylamine, diethylamide, triethylamine, tripropylamine and thanomin.

Pharmaceutical composition can be made into various formulations, for example granule, tablet, pill, suppository, capsule, suspensoid, ointment agent, lotion etc.When preparation comprises the composition of therapeutical active compound, can use the pharmaceutical grade that is suitable for oral and local use organic or inorganic carrier and/or thinner.Thinner known in the art comprises water-bearing media, plant and animal grease.Can use stablizer, wetting agent and emulsifying agent, be used to the damping fluid and the skin penetration enhancer that change the salt of osmotic pressure or be used to guarantee enough pH values as assistant agent.Pharmaceutical composition also can comprise one or more following compositions: carrier proteins, as serum albumin; Damping fluid; Filler is as Microcrystalline Cellulose, lactose, corn and other starch; Tackiness agent; Sweeting agent and other seasoningss; Tinting material; And polyoxyethylene glycol.Additive is well known in the art, and can use in various preparations.

Mitogenic agent of the present invention can carry out administration by number of ways, include but not limited in oral, subcutaneous, intravenously, the nose, in the transdermal, intraperitoneal, intramuscular, lung, vagina, rectum or intraocular.In some cases, for example when treatment wound and inflammation, antimitotic agent of the present invention can be directly with solution or sprays administration.

Being used for screening when using compound of the present invention in conjunction with the method for the compound of KSP kinesin, KSP is combined on the carrier, in experiment, add compound of the present invention (it is a mitogenic agent) then.Perhaps, compound of the present invention is combined on the carrier, adds KSP then.The non-natural wedding agent that the compound that can seek new wedding agent therein comprises specific antibody, differentiated in chemical library screening, peptide analogs etc.Filter out that to have hypotoxic drug candidate for people's cell be the useful especially aspect of screening experiment.Can use kinds of experiments for this purpose, the protein-protein that comprises external mark is in conjunction with experiment, and electrophoresis movability displacement experiment is used for protein bound immunization experiment, functional group's experiment (phosphorylation experiment etc.), or the like.

Can several different methods measure combining of mitogenic agent and KSP.In preferred embodiments, mitogenic agent (compound of the present invention) for example with fluorescence or radioactivity group mark, is directly measured combination then.For example, this can followingly carry out: KSP used or part is connected on the solid carrier, interpolation is through the mitogenic agent of mark (for example wherein the The compounds of this invention replaced by detectable isotropic substance of at least one atom), wash away excessive reagent, measure the amount of the marker that exists on the solid carrier then.As is known to persons skilled in the art, can use various blocking-up and washing step.

Term " mark " is meant compound directly or indirectly with the marker mark that detection signal can be provided, and described marker for example is emitting isotope, fluorescent mark, enzyme, antibody, particle (as magnetic-particle), chemiluminescent labeling or specific binding molecules etc.Specific binding molecules comprises a pair of material, as vitamin H and streptavidin, and digoxin and anti-digoxin etc.For specificity junction mixture, according to aforesaid currently known methods, complementary square tube molecule normal and to be detected combines.Marker can be directly or detectable signal is provided indirectly.

In certain embodiments, one of them compound of mark only.For example, available ¹²⁵I or fluorophore are at tyrosine position mark kinesin.Perhaps, with the different more than one components of marker mark, for example protein is used ¹²⁵I, and mitogenic agent fluorophore.

Competitor when compound of the present invention also can be used as other drug candidates of screening.The speech that is equal on this used term " candidate bioactive agent " or " drug candidate " or grammer is meant its bioactive any molecule to be detected, as protein, oligopeptides, little organic molecule, polysaccharide, polynucleotide etc.They can be directly or change the expression of cell proliferation phenotype or cell proliferation sequence indirectly, and described cell proliferation sequence comprises nucleotide sequence and protein sequence.In other cases, screening changes cell proliferation protein binding and/or activity.The screening of the type can be carried out when having or do not have microtubule to exist.In the screening protein binding or when active, embodiment preferred do not comprise any known can be in conjunction with concrete proteic molecule, for example polymer architecture (as microtubule) and energy source (as ATP).The preferred embodiment of experiment is included in the drug candidate (being called " exogenous " medicine at this) of debond molecule proliferin under its endogenous native state.In other embodiment preferred, exogenous medicine is further got rid of the antibody of KSP.

Drug candidate can comprise the chemical substance of plurality of classes, but organic molecule normally, preferred molecular weight is the daltonian little organic molecule of 100-2500.Drug candidate comprises and proteic structural interaction necessary functional group, particularly hydrogen bond and lipotropy bonded functional group that it comprises amine, carbonyl, hydroxyl, ether or carboxyl usually at least, has two at least in the preferred functional group.Drug candidate often comprises ring-type carbon or heterocycle structure and/or fragrance or many aromatic structures, and they are replaced by one or more above-mentioned functional group.Drug candidate also can be selected in biomolecules, and described biomolecules comprises peptide, sugar, lipid acid, steroidal compounds, purine, pyrimidine and their derivative, analog or combination.Particularly preferably be peptide.

Drug candidate is that the multiple source by the library that comprises synthetic or natural compounds obtains.For example, at random multiple mode can be arranged, and relate to the synthetic of multiple organic compound and biomolecules, comprise the expression of random oligonucleotide.Perhaps, the natural compounds library of bacterium, fungi, plant and animal form of extract also can utilize or be easy to generate.In addition, natural or synthetic library and compound can be easily chemistry, physics and biochemical method by routine carry out modification.Known drug can be carried out specific aim or chemical modification at random, as acylations, alkylation, esterification, amidation, to produce analog.

Competitive screening experiment can be undertaken by mixing KSP and drug candidate in first sample.Second sample comprises mitogenic agent, KSP and drug candidate.This can carry out when having or do not have microtubule to exist.Measure the drug candidate combination in these two samples, and between two samples in conjunction with changing or difference shows that existence can be in conjunction with KSP and its active medicine of potential adjusting.That is to say,, show that then drug candidate can be in conjunction with KSP if the combination of drug candidate is different from first sample in second sample.

In preferred embodiments, the combination of drug candidate is by using competitive binding experiment to measure.In this embodiment, competitor is known and KSP bonded binding substance, as antibody, peptide, binding partners, part etc.In some cases, for example between drug candidate and binding substance,, can there be competitive combination with binding substance replacement candidate medicine.

In one embodiment, drug candidate is through mark.Two of drug candidate or competitor or they at first are added among the KSP, and its time is enough to carry out combination.Can under any temperature that helps optimum activity, be incubated, usually between 4-40 ℃.

The time of insulation is selected according to optimum activity, but also can carry out optimizing, to help high fast output screening.Usually 0.1-1 hour is enough.Excessive reagent is removed usually or washes off.Then adding second component, is the component that has or do not pass through mark, to show combination then.

In preferred embodiments, at first add competitor, add drug candidate then.The replacement of competitor be drug candidate combine with KSP and thus can in conjunction with and the active index of potential adjusting KSP.In this embodiment, component can be carried out mark.Therefore, for example,, replaces competitor if through mark, then existing marker to show by medicine in washing soln.Perhaps, if drug candidate is labeled, on carrier, exists marker to show and replace.

In another embodiment, drug candidate at first adds, and is incubated and washs, and is competitor then.Do not exist the combination of competitor to show that drug candidate combines with KSP with higher affinity.Therefore,, on carrier, there is marker, do not have the combination of competitor, might show that drug candidate can combine with KSP if drug candidate is a mark.

The binding site that identifies KSP is very valuable.This can be undertaken by the whole bag of tricks.In one embodiment, combine with mitogenic agent in case identify KSP, just make KSP segmentation or modification, repeated experiments is to identify in conjunction with necessary component then.

Regulating effect can be regulated the active drug candidate of KSP by screening and be tested, and it may further comprise the steps: mix drug candidate and KSP as mentioned above, measure the bioactive variation of KSP then.Therefore, in this embodiment, drug candidate should combine (though this not necessarily) with KSP, and changes its biology or biochemical activity.This method comprises sieve method in cells in vitro sieve method and the body, comprising cell cycle distribution, cell survival rate, mitotic spindle whether exist, the variation of form, activity, distribution or amount.

Perhaps, can use different screenings, with identify combine with natural KSP but not with Modified K SP bonded drug candidate.

Can in experiment, use positive control and negative control.Preferably, all contrasts and specimen are all carried out three times at least, to obtain the significant result of statistics.The soaking time of all samples should be enough to make medicine and protein bound.After insulation, wash all samples, making does not have the material of non-specific binding, measure then in conjunction with and also the amount of the medicine that is labeled usually.For example, when using radioactively labelled substance, sample can be counted in scintillometer, to measure the amount of binding compounds.

In screening experiment, can comprise multiple other reagent.These reagent comprise for example salt, neutral protein matter (as albumin), washing composition etc., and they can help best protein-protein combination and/or reduce non-specific or the background interaction.Also can use the reagent that can improve service efficiency, as proteinase inhibitor, nucleic acid inhibitor, microbicide etc.Can any order add the mixture of component, to improve required combination.

Following examples are used for describing in more detail the mode of the present invention of implementing.It should be understood that these embodiment never are the restrictions to true scope of the present invention, and only be to be used for illustration purpose.All be incorporated herein by reference in full at these all reference of quoting.

Embodiment

Below the connotation of abbreviation and term is as follows:

Ac	Ethanoyl
		BNB	4-brooethyl-3-nitrobenzoic acid
Boc	The t-butoxy carbonyl
		Bu	Butyl
c-	Ring
		CBZ	Benzyloxycarbonyl
DBU	Diazabicylo [5.4.0] 11 carbon-7-alkene
		DCM	Methylene dichloride CH 2Cl 2

DCE	Ethylene Dichloride
		DEAD	The azoethane dicarboxylic ester
DIC	The di-isopropyl carbodiimide
		DIEA	N, the N-diisopropyl ethyl amine
DMAP	4-N, the N-dimethyl aminopyridine
		DMF	N, dinethylformamide
DMSO	Dimethyl sulfoxide (DMSO)
		DVB	1, the 4-Vinylstyrene
EEDQ	2-oxyethyl group-1-ethoxy carbonyl-1, the 2-dihydroquinoline
		Et	Ethyl
Fmoc	9-fluorenyl methoxy carbonyl
		GC	Gas-chromatography
HATU	O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-phosphofluoric acid urine
		HMDS	Hexamethyldisilazane
HOAc	Acetate
		HOBt	Hydroxybenzotriazole
Me	Methyl
		mesyl	Methylsulfonyl
MTBE	Methyl tertiary butyl ether
		NMO	The N-methyl morpholine oxide
PEG	Polyoxyethylene glycol
		Ph	Phenyl
Phoh	Phenol
		PfP	Pentafluorophenol
PPTS	The tosic acid pyridinium salt
		Py	Pyridine
PyBroP	Bromo-tripyrrole alkane phosphofluoric acid urine
		rt	Room temperature
sat＝d	Saturated
		s-	Secondary
t-	Three grades
		TBDMS	T-butyldimethylsilyl

TES	Triethyl silicane
		TFA	Trifluoroacetic acid
THF	Tetrahydrofuran (THF)
		TMOF	Orthoformic acid trimethylammonium ester
TMS	Trimethyl silyl
		tosyl	P-toluenesulfonyl
TrT	Trityl group

Embodiment 1

Synthesizing of compound

Total synthetic method is seen shown in Fig. 1 and 2.

Step 1:N-butyryl radicals anthranilic acid

(0.5mol 68.5g) and dimethyl formamide (250ml), is furnished with thermometer, dropping funnel and magnetic stirring bar on this round-bottomed flask to add amino o-benzoic acid (1) in 3 neck 500ml round-bottomed flasks.(0.55mol, 57.1ml), its speed should make the temperature of mixture be no more than 40 ℃ to drip butyryl chloride in this solution.At room temperature this suspension of vigorous stirring is at least 3 hours.Mixture is poured in the water (2000ml), and restir 1 hour.Filter the product that collecting precipitation goes out, use cold water washing, then under reduced pressure in P ₂O ₅Last dry, produce compound 2 (67.3g, 65%).Step 2:2-propyl group-3,1-[4H] benzoxazine-4-ketone

(51.8g 0.25mol) is dissolved in the diacetyl oxide (180ml), and this round-bottomed flask is furnished with magnetic stirring bar, Claisen still head (having vacuum inlet) and thermometer with compound 2 in the round-bottomed flask of 500ml.This flask is placed in the oil bath, under vigorous stirring, slowly is heated to 170-180 ℃ then.Slowly the acetate that is produced is removed in distillation under barometric point.The head temperature of monitoring water distilling apparatus in conversion process.Reaction mixture is cooled to 60 ℃, and under reduced pressure removes excessive acetic anhydride via (about 20mmHg) by distillation.Cool off residue then, and make the product crystallization.Product grinds with normal hexane (75ml), and filtering separation obtains 2-propyl group-3,1-[4H then] benzoxazine-4-ketone (3) (29.3g, 62%).The compound 3 that aforesaid method obtains is enough pure, and is directly used in next step.

Step 3:2-propyl group-3-benzyl quinazoline-4-one

In single port 250ml round-bottomed flask, make compound 3 (28.4g, 0.15mol) and benzylamine (17.5ml 0.16mol) refluxed in chloroform (50ml) 6 hours.After compound 3 consumes fully, the reduction vaporization chloroform.In the flask of being furnished with Claisen still head and magnetic stirring bar, add ethylene glycol (100ml) and sodium hydrate particle (0.60g) to residue.This flask is immersed in the oil bath, and is preheated to 130-140 ℃ bath temperature under vigorous stirring, kept then 5 hours, the water that is produced is removed in distillation simultaneously.After reacting completely, make settled solution be cooled to room temperature, and keep spending the night, to be settled out product.Adding 3% hydrochloric acid soln, is 7-8 with the pH regulator of suspension, filters out crystal, and uses cold water washing, uses Virahol (perhaps acetone) recrystallization then, obtains compound 2-propyl group-3-benzyl quinazoline-4-one (compound 4) (28.0g, 67%).

Step 4:2-(1 '-bromopropyl)-3-benzyl quinazoline-4-one

(27.8g, 0.10mol), sodium acetate, anhydrous (10.0g) and glacial acetic acid (130ml), this flask is furnished with thermometer, dropping funnel and stirring rod to add compound 4 in three mouthfuls of 250ml flasks.Under 40 ℃, in this solution, drip the bromine be dissolved in the acetate (10ml) (16.0g, 0.10mol), time spent 1-2 hour.After interpolation is finished, mixture is poured in the water (1500ml), and at room temperature stirred 1-2 hour.The product 2-that filtering separation is settled out (1 '-bromopropyl)-3-benzyl quinazoline-4-one (5), to remove the acetate of trace, use a spot of Virahol drip washing with the warm water washing then.Obtain compound 5 (53.0g, 92%) after the drying.

Step 5:2-[1 '-(N, N-dimethyl ethylene amido) propyl group]-3-benzyl quinazoline-4-one

(10.7g, 0.03mol) and N, (6.6ml, 0.06mol), reflux is 6 hours then for N-dimethyl ethylene diamine for dissolved compound 5 in dehydrated alcohol (60ml).After reacting completely, solvent evaporated under reduced pressure.Residue is dissolved in the methylene dichloride (150ml), uses 3% aqueous sodium hydroxide solution (about 10-20ml) washing then.The organic layer dried over mgso, reduction vaporization is to doing then.Residual oily product passes through the pure system of flash chromatography on short silicagel pad, wherein use chloroform-methanol-ammoniacal liquor 90: 10: 0.1 as eluent, obtain desirable compound (5)--2-[1 '-(N, N-dimethyl ethylene amido) propyl group]-3-benzyl quinazoline-4-one (6) (6.0g, 55%).

Step 6:2-[1 '-(N-4-fluoro benzoyl)-(N, N-dimethyl ethylene amido) propyl group]-3-benzyl quinazoline-4-one

Preparation compound 5 (1.822g, stock liquid 5.0mmol) in the chloroform (0.5ml) of HPLC level.In the flask of 2.0ml volume the preparation to fluorobenzoyl chloride (160.2mg, 1mmol) in 1 of HPLC level, the stock liquid in the 2-ethylene dichloride (2.0ml).In 1 of HPLC level, prepare triethylamine (2.0ml, solution 0.5M) in the 2-ethylene dichloride.With Beckman Biomet2000 automated fluid divider each solution of 100 μ l is moved liquid to the glass reaction container.Use mechanical shaker to shake reaction mixture, in ultrasonic water bath, carry out supersound process, then incubated overnight at room temperature.Mixture dilutes in chloroform (300 μ l), uses 5% sodium bicarbonate aqueous solution and water washing then.Solvent removed in vacuo obtains compound (6) (65%).Analyze the purity of this compound with TLC, wherein use 100: 10: 1 wash-outs of dichloromethane-ethanol-strong aqua.

Embodiment 2 and 3

The compound of synthetic formula 1d

All anhydrous solvents are all available from Aldrich Chemical Company, and are stored in

In the container.Most reagent is available from Aldrich Chemical Company.Abbreviation: DCM, methylene dichloride; DIEA, N, N-diisopropyl ethyl amine; DMF, N, dinethylformamide; TES, triethyl silicane; TFA, trifluoroacetic acid.Array synthetic (array synthesis) carries out in 15 * 75mm round bottom screw cap Glass tubing, and this Glass tubing is placed in 4 * 6 row aluminum synthesizers, with Teflon lining rubber film phonograph seal.Add reagent, carry out moisture extraction with single or hyperchannel safety pipette.Filter with Whatman/Polyfiltronics 24 holes, 10ml filtration unit.Volatile matter is carried out with Labconco vortex vaporizer or by purging with 4 * 6 nitrogen manifolds by the evaporation in the array.

Embodiment 2 (solid phase synthesis of individualized compound)

Step 1) weighing 1, (Novabiochem, 1.2mmol/g) (0.20g 0.24mmol) and be added in the screw cap Glass tubing, adds DMF and 1: 1 mixture of chloroform of 3ml to 3-diaminopropanes trityl resin then.Add DIEA (0.130ml, 0.72mmol) and 2-(1 '-bromopropyl)-3-benzyl quinazoline-4-one (preparing among the embodiment 1) (0.188g, 0.48mmol).Seal Glass tubing, be heated to 70 ℃, then shaken over night.Filter resin, and wash (3 * DCM, 2 * MeOH, 1 * DCM, 2 * ether), vacuum-drying then.The resin of 27mg equal portions was with 5: 5: 90 TFA: TES: DCM handled 15 minutes, filtered then and evaporating mixture, obtained the quinazolinone diamines intermediate of 8mg (productive rate 64%).Lcms analysis shows purity＞80%.

Step 2) swelling in the DCM of 3ml of the resin in the step 1.Add DIEA (0.130ml, 0.72mmol) and the 4-bromo benzyl bromo (0.12g, 0.48mmol).Sealed glass tube, shaken over night then.Lcms analysis cracking equal portions show have an appointment 1: 1 initiator and mixture of products.Add the DIEA of 0.130ml and the 4-bromo benzyl bromo of 0.12g again, under 70 ℃, shook mixture 8 hours then.Filter resin, washing (as mentioned above), vacuum-drying then.

Resin in the step 3) step 2 was with 5: 5: 90 TFA: TES: DCM shakes and filters 2 times.Merging filtrate also evaporates, and obtains the orange of 140mg.This material carries out pure system with anti-phase preparation HPLC (acetonitrile-water gradient), obtains single tfa salt of 27mg (is 17% for 3 steps).

Embodiment 3 (the synthetic a plurality of compounds of combination)

Step 1) is respectively with 1,2-diaminoethanes trityl resin (Novabiochem, 0.95mmol/g) (200g, 1.9mmol) and 1,3-diaminopropanes trityl resin (Novabiochem, 1.14mmol/g) (2.0g 2.28mmol) is placed in the different 10ml polypropylene sintered pipes (Bio-Rad).The 2-of the DIEA (being respectively 1.0ml and 1.2ml) of the chloroform of DMF, the 4ml of interpolation 4ml, 3eq. and 2eq. in each pipe (1 '-bromopropyl)-3-benzyl quinazoline-4-one (embodiment 1 makes) (being respectively 1.5g and 1.8g).This mixture is 70 ℃ of following shaken over night.Each mixture washs (3 * DCM, 2 * MeOH, 1 * DCM, 2 * ether), vacuum-drying then.There is suitable quinazolinone-diamines in the analysis revealed of cracking equal portions, and the purity of each is all greater than 90%.

2) put in each Glass tubing in array head 2 row quinazolinone ethyl-diamine resin (105mg, 0.10mmol), behind array, put in each Glass tubing of 2 rows then quinazolinone propyl group-diamine resin (88mg, 0.10mmol).In each Glass tubing, add DIEA (0.131ml, 0.75mmol).In each Glass tubing of array head 2 rows, add different amine, and behind array, repeat to add in 2 Glass tubings of arranging.Reaction unit is 70 ℃ of following shaken over night.By with the hyperchannel transfer pipet of choice refreshments gel-hole point by removing liquid in each Glass tubing, washing resin (2 * DCM, 1 * MeOH, 1 * DCM), and vacuum-drying then.

3) 10: 5: 85 TFA of interpolation 2ml in the Glass tubing of each in array: TES: DCM solution.Reaction unit shook 45 minutes, mixture is transferred in the filtration unit filters then, and the DCM with 0.75ml washs 2 times then.Evaporating solns obtains yellow-red oily matter.Grind these sticking oily matter 2 times with ether, be dissolved among the DCM, use 4M hcl dioxane solution-treated then, obtain hydrochloride (each compound is not known the salt of number), be the powder or the amorphous solid of brown-white.Lcms analysis shows that all purity is all greater than 75%.

Embodiment 4-6

6 racemize quinazolinones are separated into their enantiomorph with chiral chromatography.The wherein chiral chromatography of 3 compounds is below described.

Embodiment 4

Post-Chiralpak AD, 250 * 4.6mm (Diacel Inc.)

Sample-0.5mg/ml is in ethanol.

60% ethanol hexane solution of condition-15 minute, enantiomorph 1 was at 4.5 minutes wash-outs, and enantiomorph 2 was at 4.9 minutes wash-outs.

Embodiment 5

Post-Chiralcel OJ, 250 * 4.6mm (Diacel Inc.)

Sample-0.5mg/ml is in ethanol.

10% ethanol hexane solution of condition-15 minute, (R)-enantiomorph is at 8.4 minutes wash-outs, (S)-enantiomorph is at 9.6 minutes wash-outs.

Embodiment 6

Post-Chiralpak AD, 250 * 4.6mm (Diacel Inc.)

Sample-0.5mg/ml is in ethanol.

70% ethanol hexane solution of condition-15 minute, enantiomorph 1 was at 6.5 minutes wash-outs, and enantiomorph 2 was at 8.8 minutes wash-outs.

Following table has been described the racemoid of as above isolating three other compounds and the IC of enantiomorph ₅₀Active.In all three situations, an enantiomorph significantly is better than another enantiomorph.As if by independently chirality is synthetic, active stronger enantiomorph is the R enantiomorph.

Embodiment 7 and 8

Below two compounds be with the form synthetic of the route shown in Fig. 4 with single enantiomer.Data show that active stronger enantiomorph is the R enantiomorph.

Embodiment 9

Chiral separation by the tartrate recrystallization

The intermediate A that makes among the embodiment 1 can be converted into intermediate B, and it is when splitting, for 5 steps shown in Fig. 4 provide an alternative method.This method is shown in following synthetic route:

The R enantiomorph of B can selective crystallization makes mixture be back to room temperature then by heating B and the tartaric mixture of 1.1 equivalent D-in Virahol and methanol mixture.

Embodiment 9:X=Cl, R=H

Racemic intermediate B (1.5g) is dissolved in the 100ml ebullient Virahol, mixes with the solution of D-tartrate in 100ml boiling methyl alcohol of 0.8g then.Make this mixture slowly reach room temperature.After placement was spent the night, solids removed by filtration was used ethyl acetate and hexane wash then, the line space of going forward side by side air dry.The solid of drying (0.8g) is dissolved in the boiling mixture of 50ml Virahol and 50ml methyl alcohol, makes them slowly cool to room temperature then.After placement is spent the night, filter out the solid of gained, and, carry out dry air then with ethyl acetate and hexane wash.The solid of drying stirred 30 minutes with saturated sodium bicarbonate solution, used ethyl acetate extraction then.Organic phase drying (sal epsom) is filtered, and is evaporated to dried then.The clarification oily matter weight of gained is 345mg.Wherein a part is converted into the S-Mosher acid amides and uses ¹H NMR checks product, measures chiral purity thus greater than 95%.According to the remaining step among Fig. 4, the compound of the enantiomer-pure that is prepared as follows by the initial use of the material that obtains in above-mentioned steps D-and L-tartrate.

In the cell of handling with quinazolinone KSP inhibitor, induce mitotic division to stop

Followingly carry out facs analysis to measure cell cycle phase by measuring dna content.Skov-3 cell (human ovarian cancer) is split into 1: 10, is laid in the ware of 10cm, grows to inferior the fusion together with RPMI 1640 substratum that comprise 5% foetal calf serum (FBS) then.Cell uses the DMSO (carrier of compound) of 10nM taxol, 400nM quinazolinone 1,200nM quinazolinone 2 or 0.25% to handle then 24 hours.With the PBS that comprises 5mM EDTA with cell by washing in the plate, precipitation with the PBS washing that comprises 1%FCS once, is fixedly being spent the night in 85% ethanol under 4 ℃ more then.Before analyzing, make cell precipitation, washing is once dyeed half hour down in 37 ℃ in the solution of every milliliter 10 μ g iodate third ingot and 250 μ g rnases then.On Becton-Dickinson FACScan, carry out the wandering cells score and analyse, with the data of 10000 cells in each sample of Modfit software analysis.

Quinazolinones and known antimitotic agent taxol make cell move to G2/M cell cycle phase (4n dna content) by G0/G1 cell cycle phase (2n dna content).Other compounds of finding such have similar effect.

Monopolar spindle behind the administration quinazolinone KSP inhibitor forms

For measuring G2/M cumulative essence, human tumor cell line Skov-3 (ovary), HeLa (uterine cervix) and A549 (lung) are with 4000 cell (the SKOV-3 ﹠amp in every hole; HeLa) or the density of 8000 cells (A549) put into 96 orifice plates, their were adhered to 24 hours, then with the quinazolinones processing of various concentration 24 hours.Cell fixation and dyes with microtubulin-resisting antibody (use subsequently fluorescently-labeled auxiliary antibody identification) and Hoechst dyestuff (its DNA that dyes) in 4% formaldehyde.

Visual control shows that quinazolinones makes the cell cycle stop at the mitotic prometaphase.The DNA condensation, and begin to form spindle body, but the cell that stops shows as monopolar spindle equably, and this shows the separation that has suppressed the spindle polar body.The anti-KSP antibody of micro-injection also makes mitotic division stop, and the cell that stops also shows as monopolar spindle.

In the tumor cell line of handling with quinazolinone KSP inhibitor, suppress cell proliferation

With the density of 1000-2500 cells/well (depending on clone) cell is put into the hole of 96 orifice plates, made their adhesion/growths then 24 hours.Time when adding compound is as T ₀Use reagent 3-(4,5-dimethylthiazole-2-yl)-(I.S. the 5th for the experiment of the tetrazyl of 5-(3-carboxyl p-methoxy-phenyl)-2-(4-sulfo group phenyl)-2H-tetrazolium (MTS), 185, No. 450 United States Patent (USP)s) (referring to Promega products catalogue #G3580, CellTiter 96

AQ _UeousOneSolution Cell Proliferation Assay), be used to measure T ₀The time cell survival quantity and the quantity of contact compound survivaling cell after 48 hours.Survivaling cell quantity when the survival cells amount is with the interpolation medicine after 48 hours is compared, to calculate the growth-inhibiting effect.

The growth of cell after 48 hours is considered to 100% growth in the control wells of only using carrier (0.25%DMSO) to handle, and the cell growth in the hole of interpolation compound compares with it.Quinazolinone KSP inhibitor suppresses the cell proliferation of the human tumor cell line of following tumor type: lung (NCI-H460, A549), mammary gland (MDA-MB-231, MCF-7, MCF-7/ADR-RES), colon (HT29, HCT15), ovary (SKOV-3, OVCAR-3), leukemia (HL-60 (TB), K-562), central nervous system (SF-268), kidney (A498), osteosarcoma (U2-OS) and uterine cervix (HeLa).In addition, when quinazolinones is arranged, also mouse tumour system (B16, melanoma) is produced the growth-inhibiting effect.

GI ₅₀Be the per-cent mapping of handling cell growth in the hole to be calculated by compound concentrations (μ M).GI for compound calculating ₅₀Be to compare 50% estimated concentration when suppressing growth with control group, promptly, the concentration of time of representing of following equation:

100 * [(handle 48 hours-T ₀48 hours-T of)/(contrast ₀)]=50

All compound concentration test doubles, and contrast is the mean value in 12 holes.NationalCancer Institute has used very similar 96 orifice plate scheme and GI ₅₀Method of calculation (referring to: people such as Monks, J.Natl.Cancer Inst.83:757-766 (1991)).But the method that National CancerInstitute is used for quantitative cell number is not to use MTS, and is to use other method.

IC ₅₀Calculating

The compounds of this invention is to the active IC of KSP ₅₀Value is to use the ATP enzyme to test and measures.Use following solution: solution 1 is made up of the magnesium chloride (VWRJT400301) of Pipes/KOH pH 6.8 (Sigma P6757), the 2mM of the froth breaking 289 (Sigma A-8436) of the taxol (Sigma T-7402) of IDTT (Sigma D-9779), the 5 μ M of ATP (Sigma A-3377), the 1mM of the phosphorus olefin(e) acid alcohol potassium pyruvate salt (Sigma P-7127) of 3mM, 2mM, 10ppm, 25mM and the EGTA (Sigma E3889) of 1mM.Solution 2 is by the NADH (SigmaN8129) of 1mM, 0.2mg/ml BSA (SigmaA7906), pyruvate kinase 7U/ml, L-lactic dehydrogenase 10 U/ml (Sigma P0294), the KSP motion field of 100nM, the microtubule of 50 μ g/ml, the DTT of 1mM (Sigma D9779), the taxol of 5 μ M (Sigma T-7402), the froth breaking 289 of 10ppm (Sigma A-8436), the Pipes/KOH pH 6.8 of 25mM (Sigma P6757), the magnesium chloride of 2mM (VWR JT4003-01), and the EGTA of 1mM (Sigma E3889) forms.Use solution 1 to go up the serial dilutions (8-12 2 times of diluents) of preparation compound at 96 orifice plates (CorningCostar3695).Behind serial dilution, there is the solution 1 of 50 μ l in each hole.In each hole, add the solution 2 of 50 μ l, make the reaction beginning thus.This can realize by manual use hyperchannel transfer pipet or with the automated fluid treatment unit.Microtiter plate is transferred in the microplate absorbancy reader, and dynamically to read a plurality of absorbancy readings of each hole at the 340nm place.Viewed rate of change is directly proportional with the ATP enzyme, and draws the figure that it changes with compound concentration.For IC standard ₅₀Measure, needed data are to carry out match by the equation use nonlinear fitting program (as Grafit 4) of following 4 parameters:

Wherein y is observed speed, and x is a compound concentration.

Quinazolinones suppresses the growth of various clones, comprises that express P-glycoprotein (is also referred to as multiple medicines thing resistance, perhaps MDR ⁺) clone (MCF-7/ADR-RES, HCT15), described glycoprotein can produce resistance to other treatment agent such as taxol.Therefore, quianzolinones is the antimitotic agent that can suppress cell proliferation, and can be owing to the MDR of resistant tumors clone ⁺Overexpression and being tolerated.

Though GI ₅₀Value changes, but finds that such other compounds all suppress cell proliferation.The GI of the quinazolinones of being tested ₅₀Value at 200nM to being higher than the highest test concentrations.Thus, do not suppress cell proliferation though great majority suppress the active compound of KSP on biological chemistry, for certain some, when the highest test concentrations (being generally about 20 μ M), the cell growth has been suppressed below 50%.The GI of chemical compound lot ₅₀Value is lower than 10 μ M, and the GI of some is arranged ₅₀Value is lower than 1 μ M.Be successfully used to treat the GI of the anti-proliferative compounds of cancer (cancer chemotherapeutic agents) clinically ₅₀In very large range change.For example, in the A549 cell, the GI of taxol ₅₀Be 4nM, Dx is 63nM, and 5 FU 5 fluorouracil is 1 μ M, and hydroxyurea is 500 μ M (these data are by National Cancer Institute, and Development TherapeuticProgram provides, http://dtp.nci.nih.gov/).Therefore, can use under any actually concentration all compounds of propagation capable of inhibiting cell.But preferably, the GI of compound ₅₀Value is lower than 1mM.More preferably, the GI of compound ₅₀Value is lower than 20 μ M.More preferably, the GI of compound ₅₀Value is lower than 10 μ M.GI ₅₀The further reduction of value is also wished, comprises the GI of compound ₅₀Value is lower than 1 μ M.For some quinazolinones of the present invention, the GI when it suppresses cell proliferation ₅₀Value is in being lower than the scope that 20nM-is lower than 10nM.

Claims (18)

1, a kind of compound, it is selected from following group:

Wherein:

R ₁Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₂And R ₂' be independently selected from hydrogen, alkyl, oxa alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl; Perhaps R ₂And R ₂' form 3-7 unit together to encircle;

R ₃" be selected from alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl and substituted alkyl heteroaryl;

R ₄Be selected from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl, substituted alkyl aryl, substituted heteroaryl, substituted alkyl heteroaryl and R ₁₆-alkylidene group;

R ₅, R ₆, R ₇And R ₈Be independently selected from hydrogen, alkyl, alkoxyl group, halogen, fluoro-alkyl, nitro, dialkyl amido, alkyl sulphonyl, alkylsulfamoyl group, sulfamoyl alkyl, sulfamyl aryl, alkylthio, carboxyalkyl, carboxamide groups, aminocarboxyl, aryl and heteroaryl;

R ₁₆Be selected from alkoxyl group, amino, alkylamino, dialkyl amido, N-heterocyclic radical and replace the N-heterocyclic radical;

And acceptable salt on the pharmacology.

2, compound as claimed in claim 1, wherein,

R ₁Be selected from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, miscellaneous alkyl aryl and substituted alkyl aryl,

R ₂Be selected from hydrogen, alkyl or substituted alkyl,

R ₂' be hydrogen,

R ₄Be selected from alkyl, aryl, alkylaryl, miscellaneous alkyl aryl, substituted alkyl, substituted aryl and R ₁₆-alkylidene group,

R ₅Be hydrogen,

R ₆, R ₇And R ₈Be independently selected from hydrogen, halogen, methyl and trifluoromethyl,

R ₁₆Be selected from alkoxyl group, amino, alkylamino, dialkyl amido and N-heterocyclic radical.

3, compound as claimed in claim 1, wherein

R ₁Be benzyl or halogeno-benzyl;

R ₂Be selected from ethyl and propyl group;

R ₂' be hydrogen;

R ₃" be substituted-phenyl;

R ₄Be-(CH) _mOH or-(CH ₂) _pR ₁₆, wherein m is 2 or 3, p is 1-3;

R ₅Be hydrogen;

R ₆Be hydrogen;

R ₇It is halogen;

R ₈Be hydrogen; And

R ₁₆Be selected from amino, propyl group amino and azetidinyl.

4, compound as claimed in claim 1, it has with following formula:

5, compound as claimed in claim 4, wherein

R ₁Be selected from low alkyl group, benzyl, substituted benzyl, phenyl, naphthyl and the substituted-phenyl of hydrogen, low alkyl group, replacement;

R ₂Be selected from the low alkyl group of hydrogen, low alkyl group and replacement;

R ₂' be hydrogen;

R ₄Be selected from low alkyl group, cyclohexyl, by the phenyl that hydroxyl, lower alkoxy or low alkyl group replace, benzyl, heteroaryl methyl, heteroaryl ethyl, heteroaryl propyl group and R ₁₆-alkylidene group, wherein R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, lower alkoxy or N-heterocyclic radical.

6, compound as claimed in claim 4, wherein

R ₁Be selected from low alkyl group, benzyl, substituted benzyl and substituted-phenyl;

R ₂Be hydrogen or low alkyl group;

R ₂' be hydrogen;

R ₄Be R ₁₆-alkylidene group;

R ₇Be selected from hydrogen, fluorine, chlorine and methyl;

R ₅, R ₆And R ₈Be hydrogen;

R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, pyrrolidyl, piperidyl, imidazolyl and morpholinyl.

7, compound as claimed in claim 1, it has with following formula:

8, compound as claimed in claim 7, wherein

R ₁Be selected from low alkyl group, benzyl, substituted benzyl, phenyl, naphthyl and the substituted-phenyl of hydrogen, low alkyl group, replacement;

R ₂Be selected from the low alkyl group of hydrogen, low alkyl group and replacement;

R ₂' be hydrogen;

R ₃" be selected from C ₁-C ₁₃The low alkyl group of alkyl, replacement, phenyl, naphthyl, the phenyl, xenyl, benzyl and the heterocyclic radical that are replaced by halogen, low alkyl group, lower alkoxy, nitro, methylene-dioxy or trifluoromethyl;

R ₄Be selected from low alkyl group, the cyclohexyl of low alkyl group, replacement, by the phenyl that hydroxyl, lower alkoxy or low alkyl group replace, benzyl, substituted benzyl, heterocyclic radical, heteroaryl methyl, heteroaryl ethyl, heteroaryl propyl group and R ₁₆-alkylidene group, wherein

R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, lower alkoxy or N-heterocyclic radical.

9, compound as claimed in claim 8, wherein

R ₁Be selected from low alkyl group, benzyl, substituted benzyl and substituted-phenyl;

R ₂Be hydrogen or low alkyl group;

R ₂' be hydrogen;

R ₃" be selected from substituted-phenyl, heterocyclic radical and naphthyl;

R ₄Be selected from the low alkyl group and the R of substituted benzyl, heterocyclic radical replacement ₁₆-alkylidene group;

R ₆And R ₇Be selected from hydrogen and halogen;

R ₅And R ₈Be hydrogen;

R ₁₆Be selected from two (low alkyl groups) amino, (low alkyl group) amino, amino, pyrrolidyl, piperidyl, imidazolyl and morpholinyl.

10, compound as claimed in claim 9, wherein

R ₁It is benzyl;

R ₂It is ethyl;

R ₂' be hydrogen;

R ₃" be selected from halogenophenyl, phenyl polyhalide base, tolyl, 3,5-dimethylphenyl, p-methoxy-phenyl, Dimethoxyphenyl, cyano-phenyl, trifluoromethyl, Trifluoromethoxyphen-l, two (trifluoromethyl) phenyl, carboxyl phenyl, tert-butyl-phenyl, methoxycarbonyl phenyl, piperidyl and naphthyl;

R ₄Be selected from substituted benzyl, piperidyl, hydroxyl (low alkyl group) and R ₁₆-alkylidene group;

R ₆And R ₇Be selected from hydrogen and halogen;

R ₅And R ₈Be hydrogen;

R ₁₆Be selected from dimethylamino, amino, pyrrolidyl and piperidyl.

11, as claim 2,3,5,6 and the described compound of one of 8-10, wherein R ₂And R ₂' three-dimensional the center that connected is the R configuration.

12, pharmaceutical composition, it comprises as acceptable carrier or vehicle on described compound of one of claim 1-11 and the pharmacology.

13, be used for the treatment of application in the medicine of cell proliferation disorders as the described compound of one of claim 1-11 in preparation.

14, be used for the treatment of application in the medicine with the active diseases associated of KSP kinesin as the described compound of one of claim 1-11 in preparation.

15, as claim 13 or 14 described application, wherein said disease is selected from following group: cancer, hyperplasia, restenosis, megalocardia, Immunological diseases and inflammation.

16, be used for suppressing the application of the medicine of KSP kinesin in preparation as the described compound of one of claim 1-11.

17, a kind of method of screening KSP kinesin conditioning agent, it comprises:

(a) make kinesin, candidate bioactive agent and as the described compound of one of claim 1-11; Then

(b) measure described candidate bioactive agent to the active effect of described kinesin.

18, the method for a kind of screening and KSP kinesin bonded compound, it comprises:

(a) make kinesin, candidate bioactive agent and through mark as the described compound of one of claim 1-11; Then

(b) measuring described candidate bioactive agent combines with described kinesin is active.

Images